Pages that link to "Item:Q2509662"

The following pages link to (Q2509662):

Displayed 19 items.

• Preclinical and clinical development of innovative GPR40 receptor agonist in the treatment of type II diabetes (Q77901) ‎ (← links)
• Selective JAK inhibitor in the treatment of immune-mediated diseases (Q77949) ‎ (← links)
• Preclinical and clinical development of first class, innovative bispecific immunotherapy as a candidate for cancer immunotherapy (Q77985) ‎ (← links)
• Developing an innovative, first-class, low-molecular, double-oriented, immunomodulatory and cytotoxic therapy as a candidate for the treatment of leukaemias and solid tumours (Q78032) ‎ (← links)
• New S-ketamine therapy to treat drug-resistant depression. (Q78542) ‎ (← links)
• Preclinical and clinical development of an innovative lipid kinase inhibitor as a candidate for steroid-resistant and severe inflammatory pulmonary diseases. (Q78715) ‎ (← links)
• Preclinical and clinical development of ubiquitin-proteasom pathway inhibitor as an innovative medicine used in cancer therapy (Q78864) ‎ (← links)
• Development of a CHO cell-based and innovative expressive system of biosimilar production platform and preclinical and clinical development of a biosimilar drug based on the Fab fragment (Q78867) ‎ (← links)
• Preclinical and clinical development of innovative TrkB agonists in the treatment of nervous system diseases (Q78893) ‎ (← links)
• Development of an innovative Phage Display based platform for the production of bispecific constructs and the development of preclinical and clinical development of an innovative bispecific drug candidate in the treatment of inflammatory diseases. (Q79998) ‎ (← links)
• Preclinical and clinical development of an innovative PI3 delta kinase inhibitor as a candidate in the treatment of inflammatory diseases. (Q80005) ‎ (← links)
• Expansion of the structure and research facilities of Celon Pharma S.A. through the construction of the Development Research Centre (Q80597) ‎ (← links)
• New treatment of diabetes using FGF1 protein analogue. (Q84115) ‎ (← links)
• Implementation of CELON PHARMA S.A. and development of CPL409116, an innovative inhibitor of JAK and ROCK kinases as an oral drug in the treatment of idiopathic pulmonary fibrosis. (Q2686465) ‎ (← links)
• Clinical evaluation of Phase II and verification of predictive response factors for CPL500036 — an innovative PDE10 inhibitor in the treatment of L-DOPA-induced dyskinesia in Parkinson’s disease (Q2686508) ‎ (← links)
• Development and implementation of an innovative antiviral therapist in the treatment of COVID-19 and influenza infections in clinical trials and business of its own company (Q2686527) ‎ (← links)
• Serotonergic analgesic therapy based on 5-HT7 receptor agonist (STEP7) (Q2686647) ‎ (← links)
• In vivo validation, toxicological development and implementation for clinical trials and own company activities, candidate for inhalation drug in the therapy of inflammatory and fibrotic lung diseases including COVID-19 complications (Q4416973) ‎ (← links)
• Development and implementation of innovative therapy based on GPR40 receptor agonism in neuropathic pain therapy. (Q4417773) ‎ (← links)